Sustained Response to Golimumab Predicts Good Outcomes in Ulcerative Colitis Sustained Response to Golimumab Predicts Good Outcomes in Ulcerative Colitis

Continuous clinical response (CCR) to golimumab treatment is associated with favorable outcomes in patients with moderate to severe ulcerative colitis (UC), according to a post hoc analysis of the PURSUIT-M trial.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Gastroenterology News Source Type: news